Compare LQDA & BMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LQDA | BMA |
|---|---|---|
| Founded | 2004 | 1966 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.4B |
| IPO Year | 2020 | 2006 |
| Metric | LQDA | BMA |
|---|---|---|
| Price | $78.03 | $91.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $41.00 | ★ $99.33 |
| AVG Volume (30 Days) | ★ 2.4M | 307.5K |
| Earning Date | 05-08-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 4.99% |
| EPS Growth | ★ 51.81 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $158,320,000.00 | N/A |
| Revenue This Year | $278.87 | $16.25 |
| Revenue Next Year | $57.13 | N/A |
| P/E Ratio | $147.92 | ★ $33.22 |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $38.30 |
| 52 Week High | $78.25 | $106.15 |
| Indicator | LQDA | BMA |
|---|---|---|
| Relative Strength Index (RSI) | 75.44 | 53.35 |
| Support Level | $31.23 | $84.83 |
| Resistance Level | N/A | $94.19 |
| Average True Range (ATR) | 4.14 | 4.56 |
| MACD | 0.40 | -0.97 |
| Stochastic Oscillator | 91.55 | 40.23 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.